脂質過酸化と血小板活性化は,ネズミの動脈硬化症において起こります
1Center for Experimental Therapeutics, Department of Pharmacology, University of Pennsylvania, Philadelphia, USA.
Circulation
|October 17, 2001
まとめ
脂質過酸化と血小板活性化は,動脈硬化で同時に起こる. 抗酸化物質と血小板阻害剤を組み合わせることで,ヒトの大動脈硬化症の進行を防ぐための新しい戦略を提供することができる.
科学分野:
- 心血管研究 循環器科の研究
- 動脈硬化症の病原性 病原性
- 酸化ストレス生物学 生物学
背景:
- 脂質過酸化と血小板活性化は,動脈硬化に関連しています.
- 動脈硬化におけるこれらの要因の間のインビボ相互作用は不明である.
研究 の 目的:
- 動脈硬化症における脂質過酸化と血小板活性化の相互作用を調査する.
- これらの経路を標的とした治療の可能性を評価する.
主な方法:
- 高脂肪食のLDL受容体欠乏症 (LDLR(-/-)) のマウスを動脈硬化を引き起こすために使用しました.
- 尿中の8,12-イソ-イソプロスタンF ((2α) -VIと2,3-ディノール-トロンボキサンB ((2) をマーカーとして測定した.
- ビタミンE (抗酸化物質) とインドメタシン (血小板阻害剤) を単独または併用して投与する.
主要な成果:
- 高脂肪食は,脂質過酸化と血小板活性化のマーカーの増加による動脈硬化を引き起こす.
- ビタミンEは動脈硬化症を65%減少させましたが,脂質レベルやトロンボキサンBには影響しませんでした.
- 併用療法は,マーカーと動脈硬化症の両方を80%大幅に低下させ,炎症マーカーも低下させました.
結論:
- In vivoの脂質過酸化と血小板活性化は,ネズミ動脈硬化症の異なるが共存するプロセスである.
- 酸化ストレスと血小板活性化は,アテロゲネシスの別々の治療標的である.
- 抗酸化物質と抗血小板剤を併用した治療は,人間の動脈硬化症の進行を予防する有望な結果を示しています.
関連する概念動画
Inflammation
Overview
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease I: Introduction
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...


